A5012134047- Immune Cell Function and Interaction
- Immune cells in cancer
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Cytomegalovirus and herpesvirus research
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Glioma Diagnosis and Treatment
- Cancer Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Pharmacological Effects of Natural Compounds
- Radiomics and Machine Learning in Medical Imaging
- Nanoparticle-Based Drug Delivery
- CRISPR and Genetic Engineering
- Ferroptosis and cancer prognosis
- Neuroinflammation and Neurodegeneration Mechanisms
- Brain Metastases and Treatment
- Acute Ischemic Stroke Management
- Breast Cancer Treatment Studies
- Musculoskeletal pain and rehabilitation
- Cell Image Analysis Techniques
- Acne and Rosacea Treatments and Effects
- Dermatology and Skin Diseases
- RNA Interference and Gene Delivery
Universitat Rovira i Virgili
2020-2022
University of Bergen
2013-2021
Hospital de Tortosa Verge de la Cinta
2020
Institute for Biomedicine
2014
Glioblastomas (GBMs) are lethal brain cancers that resistant to current therapies. We investigated the cytotoxicity of human allogeneic NK cells against patient-derived GBM in vitro and vivo, as well mechanisms mediating their efficacy. demonstrate KIR2DS2 immunogenotype were more potent killers, notwithstanding absence inhibitory killer Ig-like receptor (KIR)-HLA ligand mismatch. FACS-sorted enriched KIR2DS2(+) cell subpopulations retained significantly high levels CD69 CD16 when contact...
Glioblastoma (GBM) is the most aggressive brain malignancy in adults, where survival approximately 14.6 months. Novel therapies are urgently needed and immunotherapy has hailed a new dawn for treatment of solid tumors. Natural killer (NK) cells may be amenable therapeutic effectors against heterogeneous GBM, since they also do not require co-stimulation antigen specificity. However, it unclear how culture media routinely used pre-clinical studies affect GBM cell responses to NK mediated...
Resistance to temozolomide (TMZ) is due in part enhanced DNA repair mediated by high expression of O6-methyl guanine methyltransferase (MGMT) that often characterised unmethylated promoter. Here, we investigated pre-treatment glioblastoma (GBM) cells with the 26S-proteasome inhibitor bortezomib (BTZ) as a strategy interfere MGMT and thus sensitise them TMZ.Cell lines patient GBM-derived were examined vitro, latter also implanted orthotopically into NOD-SCID C.B.-Igh-1b/lcrTac-Prkdc mice...
Background: Natural killer (NK) cells are potential effectors in anti-cancer immunotherapy; however only a subset potently kills cancer cells. Here, we examined whether pretreatment of glioblastoma (GBM) with the proteasome inhibitor, bortezomib (BTZ), might sensitize tumour to NK cell lysis by inducing stress antigens recognized NK-activating receptors. Methods: Combination immunotherapy BTZ was studied vitro against GBM and GBM-bearing mouse model. Tumour were derived from primary GBMs...
By affecting immunological presentation, the presence of cytomegalovirus in some glioblastomas may impact progression. In this study, we examined a hypothesized role for natural killer (NK) cells impacting disease progression setting. We characterized 108 glioblastoma patients and 454 healthy controls HLA-A,-B,-C, NK-cell KIR receptors, CMV-specific antibodies correlated these metrics with clinical parameters. Exome sequences from large validation set control individuals were silico...
There are currently no established radiological parameters that predict response to immunotherapy. We hypothesised multiparametric, longitudinal magnetic resonance imaging (MRI) of physiological and pharmacokinetic models might detect early biological responses immunotherapy for glioblastoma targeting NG2/CSPG4 with mAb9.2.27 combined natural killer (NK) cells. Contrast enhanced conventional T1-weighted MRI at 7±1 17±2 days post-treatment failed differences in tumour size between the...
Glioblastoma is a deadly brain cancer with limited treatment options. Targeting chondroitin sulfate proteoglycan 4 (CSPG4, best known as NG2) the monoclonal antibody mAb9.2.27 and activated natural killer (NK) cells abrogated tumor growth prolonged survival of glioblastoma-bearing animals by favoring establishment pro-inflammatory microenvironment. The combination NK recruited ED1+CCR2low macrophages that stimulated ED1+ED2lowMHCIIhigh microglial to exert robust cytotoxicity. Our findings...
Abstract Background Glioblastoma (GBM) is an aggressive malignant brain tumor where median survival approximately 15 months after best available multimodal treatment. Recurrence inevitable, largely due to O 6 methylguanine DNA methyltransferase ( MGMT ) that renders the tumors resistant temozolomide (TMZ). We hypothesized pretreatment with bortezomib (BTZ) 48 hours prior TMZ deplete levels would be safe and tolerated by patients recurrent GBM harboring unmethylated promoter. The secondary...
Human cytomegalovirus (HCMV) antigens in glioblastoma (GBM) present opportunities for personalised immunotherapy. However, their presence GBM tissue is still under debate, and evidence of impact on functional immune responses prognosis sparse. Here, we investigated the pp65 (UL83) immediate early 1 (IE-1) HCMV a cohort Norwegian patients (n = 177), using qPCR, immunohistochemistry, serology. status was then used to investigate whether viral influenced cell phenotype, infiltration, activation...
The implementation of prevention strategies can reduce the risk having a stroke. This prospective, longitudinal, multicenter observational study 82 patients describes health habits, quality life, coping strategies, and physical neurological status at 3 months 1 year after EuroQoL-5D life scale (EQ-5D) strategy measurement (COPE-28) were used to assess pain discomfort, behavioral lifestyle changes. Significant differences observed in or discomfort levels those with Correlation was also found...
The axillary lymph nodes (ALNs) in breast cancer patients are the body regions to where tumoral cells most often first disseminate. tumour immune response is important for patient outcome, and some studies have evaluated its involvement ALN metastasis development. Most focused on intratumoral response, but very few peritumoral response. aim of present article evaluate infiltrates area their association with presence metastases.The concentration 11 markers areas was studied 149 diagnosed...
Abstract Background: Glioblastoma with unmethylated O6-methyl guanine DNA methyltransferase (MGMT) promoter is highly resistant to temozolomide (TMZ) chemotherapy. Strategies that ameliorate drug resistance are sorely needed. Recent trials of the proteasome inhibitor bortezomib (BTZ) (Velcade) in combination various drugs failed due inappropriate schedule timing and dosing. We hypothesized pretreatment BTZ prior TMZ administration may sensitize glioblastoma cell Methods: investigated...
Abstract Glioblastoma (GBM) is the most malignant brain tumor, where patients' survival remains dismally low despite multimodal therapies. Due to immune suppressed status of GBM patients, adoptive cellular immunotherapy might represent an attractive therapeutic strategy. We hypothesized that allogeneic NK cells may be potent effectors against due their direct cytotoxicity and immunomodulatory properties through cytokine production. Nevertheless, it not known how concurrent inhibitory...
Abstract Glioblastoma (GBM) is the most malignant and frequent brain tumor. Despite combined surgery, chemo- radiotherapy, GBM patients' survival remains very low, emphasizing need for further development of novel therapies. The promising strategy adoptive cellular immunotherapy. Studies investigating purified Natural Killer (NK) cells in transfer therapies solid tumors are sparse. Most clinical trials patients have used Lymphokine Activated (LAK) that composed T-lymphocytes NK cells, where...
<div>Abstract<p>By affecting immunological presentation, the presence of cytomegalovirus in some glioblastomas may impact progression. In this study, we examined a hypothesized role for natural killer (NK) cells impacting disease progression setting. We characterized 108 glioblastoma patients and 454 healthy controls <i>HLA-A,-B,-C</i>, NK-cell KIR receptors, CMV-specific antibodies correlated these metrics with clinical parameters. Exome sequences from large...
<p>Supplementary figures and tables for bioinformatic analyses. Fig S1 TCGA bioinformatics analysis workflow chart S2 alignment plots of quality score accuracy S3 Screenshot region interest on Chr 19 indicating genotype information KIR2DS4 variant call Table SI Characteristics the patients control population used in this study SII Clinical data 300 GBM patient obtained from The Cancer Genome Atlas (TCGA) project. SIII Description 2504 1000 Project. SIV Antibodies Flow cytometry</p>
<p>Supplementary figures legends</p>
<p>Supplementary materials and methods. Detailed bioinformatics analysis methods (softwares commands parameters) used to analyse in silicon TCGA OKG exam sequencing data.</p>
<p>Supplementary figures legends</p>